Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 233

1.

N-cadherin expression is associated with acquisition of EMT phenotype and with enhanced invasion in erlotinib-resistant lung cancer cell lines.

Zhang X, Liu G, Kang Y, Dong Z, Qian Q, Ma X.

PLoS One. 2013;8(3):e57692. doi: 10.1371/journal.pone.0057692. Epub 2013 Mar 8.

2.

Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.

Suda K, Tomizawa K, Fujii M, Murakami H, Osada H, Maehara Y, Yatabe Y, Sekido Y, Mitsudomi T.

J Thorac Oncol. 2011 Jul;6(7):1152-61. doi: 10.1097/JTO.0b013e318216ee52.

3.

Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs.

Ahmad A, Maitah MY, Ginnebaugh KR, Li Y, Bao B, Gadgeel SM, Sarkar FH.

J Hematol Oncol. 2013 Oct 7;6(1):77. doi: 10.1186/1756-8722-6-77.

4.

Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.

Zhou J, Wang J, Zeng Y, Zhang X, Hu Q, Zheng J, Chen B, Xie B, Zhang WM.

Oncotarget. 2015 Dec 29;6(42):44332-45. doi: 10.18632/oncotarget.6293.

5.

Mechanism of c-Met and EGFR tyrosine kinase inhibitor resistance through epithelial mesenchymal transition in non-small cell lung cancer.

Rastogi I, Rajanna S, Webb A, Chhabra G, Foster B, Webb B, Puri N.

Biochem Biophys Res Commun. 2016 Sep 2;477(4):937-44. doi: 10.1016/j.bbrc.2016.07.003. Epub 2016 Jul 7.

PMID:
27396618
6.

Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors.

Morgillo F, Cascone T, D'Aiuto E, Martinelli E, Troiani T, Saintigny P, De Palma R, Heymach JV, Berrino L, Tuccillo C, Ciardiello F.

Br J Cancer. 2011 Jul 26;105(3):382-92. doi: 10.1038/bjc.2011.244. Epub 2011 Jul 12.

7.

Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification.

La Monica S, Caffarra C, Saccani F, Galvani E, Galetti M, Fumarola C, Bonelli M, Cavazzoni A, Cretella D, Sirangelo R, Gatti R, Tiseo M, Ardizzoni A, Giovannetti E, Petronini PG, Alfieri RR.

PLoS One. 2013 Oct 22;8(10):e78656. doi: 10.1371/journal.pone.0078656. eCollection 2013.

8.

Protein kinase Cα mediates erlotinib resistance in lung cancer cells.

Abera MB, Kazanietz MG.

Mol Pharmacol. 2015 May;87(5):832-41. doi: 10.1124/mol.115.097725. Epub 2015 Feb 27.

9.

The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma.

Wu F, Li J, Jang C, Wang J, Xiong J.

Int J Clin Exp Pathol. 2014 Sep 15;7(10):6653-61. eCollection 2014.

10.

Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.

Li L, Han R, Xiao H, Lin C, Wang Y, Liu H, Li K, Chen H, Sun F, Yang Z, Jiang J, He Y.

Clin Cancer Res. 2014 May 15;20(10):2714-26. doi: 10.1158/1078-0432.CCR-13-2613. Epub 2014 Mar 18.

11.

Collateral chemoresistance to anti-microtubule agents in a lung cancer cell line with acquired resistance to erlotinib.

Mizuuchi H, Suda K, Sato K, Tomida S, Fujita Y, Kobayashi Y, Maehara Y, Sekido Y, Nishio K, Mitsudomi T.

PLoS One. 2015 Apr 14;10(4):e0123901. doi: 10.1371/journal.pone.0123901. eCollection 2015.

12.

Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs.

Chung JH, Rho JK, Xu X, Lee JS, Yoon HI, Lee CT, Choi YJ, Kim HR, Kim CH, Lee JC.

Lung Cancer. 2011 Aug;73(2):176-82. doi: 10.1016/j.lungcan.2010.11.011. Epub 2010 Dec 17.

PMID:
21168239
13.

Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors.

Ghosh G, Lian X, Kron SJ, Palecek SP.

BMC Cancer. 2012 Mar 20;12:95. doi: 10.1186/1471-2407-12-95.

14.

Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells.

Xie M, Zhang L, He CS, Xu F, Liu JL, Hu ZH, Zhao LP, Tian Y.

J Cell Biochem. 2012 May;113(5):1501-13. doi: 10.1002/jcb.24019.

PMID:
22173954
16.

Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.

Xie M, He CS, Wei SH, Zhang L.

Eur J Cancer. 2013 Nov;49(16):3559-72. doi: 10.1016/j.ejca.2013.07.007. Epub 2013 Aug 2.

PMID:
23916913
17.

Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.

Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, Fu L, Pham TQ, Soriano R, Stinson J, Seshagiri S, Modrusan Z, Lin CY, O'Neill V, Amler LC.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8686-98.

18.
19.

Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation.

Kim HR, Kim WS, Choi YJ, Choi CM, Rho JK, Lee JC.

Mol Oncol. 2013 Dec;7(6):1093-102. doi: 10.1016/j.molonc.2013.08.001. Epub 2013 Aug 20.

20.

Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo.

Cufí S, Bonavia R, Vazquez-Martin A, Oliveras-Ferraros C, Corominas-Faja B, Cuyàs E, Martin-Castillo B, Barrajón-Catalán E, Visa J, Segura-Carretero A, Joven J, Bosch-Barrera J, Micol V, Menendez JA.

Sci Rep. 2013;3:2459. doi: 10.1038/srep02459.

Supplemental Content

Support Center